Completed NA INTERVENTIONAL NCT00002032
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Sponsor: Pharmacia
Interventions
Rifabutin
Updated 6 times since 2017 Last updated: Jun 23, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on HIV Infections and Mycobacterium Avium-intracellulare Infection, this trial is completed. The trial is conducted by Pharmacia and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Pharmacia
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .